SEARCH:   Advanced

Blood, 15 December 2005, Vol. 106, No. 13, pp. 4057-4065. Prepublished online as a Blood First Edition Paper on August 23, 2005; DOI 10.1182/blood-2005-03-1004. This Article Full Text (PDF) All Versions of this Article: 2005-03-1004v1 106/13/4057    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Eliopoulos, N. Articles by Galipeau, J. Search for Related Content PubMed PubMed Citation Articles by Eliopoulos, N. Articles by Galipeau, J. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 15, 2005 Accepted August 11, 2005 Allogeneic marrow stromal cells are immune rejected by MHC class I and II mismatched recipient mice Nicoletta Eliopoulos, John Stagg, Laurence Lejeune, Sandra Pommey, and Jacques Galipeau* Lady Davis Institute for Medical Research, McGill University, Montreal, Quebec, Canada Lady Davis Institute for Medical Research, McGill University, Montreal, Quebec, Canada; Division of Hematology/Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada * Corresponding author; email: jacques.galipeau{at}mcgill.ca. It has been suggested that marrow stromal cells (MSCs) may be immunoprivileged and can engraft in allogeneic recipients with intact immune systems. We determined if the implantation of murine MSCs engineered to release erythropoietin (Epo) would be feasible in MHC-mismatched allogeneic mice without immunosuppression and we monitored hematocrit (Hct) as a reporter of MSC graft survival. MSCs from C57Bl/6 mice were engineered to release murine Epo (Epo+MSCs) and implanted subcutaneously in either syngeneic C57Bl/6 mice or MHC mismatched Balb/c mice. In syngeneic recipients, the Hct rapidly rose from baseline level and remained >88% for >200 days. However, in MHC-mismatched recipient Balb/c mice, the Hct rose transiently and rapidly declined to baseline values. Repeat implantations in these same mice were associated with an acquired refractoriness in the Hct response consistent with alloimmunization to donor Epo+MSCs. Allogeneic MSC implants had an increased proportion of host-derived lymphoid CD8+, NK T, and NK infiltrating cells compared with syngeneic controls, and splenocytes isolated from implanted Balb/c mice also displayed a significant IFN response to C57Bl/6 MSCs in vitro. These results strongly suggest that MSCs are not intrinsically immunoprivileged and cannot serve as a "universal donor" in immunocompetent MHC mismatched recipients. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. Francois, R. Romieu-Mourez, S. Stock-Martineau, M.-N. Boivin, J. L. Bramson, and J. Galipeau Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties Blood, September 24, 2009; 114(13): 2632 - 2638. [Abstract] [Full Text] [PDF] R. Romieu-Mourez, M. Francois, M.-N. Boivin, M. Bouchentouf, D. E. Spaner, and J. Galipeau Cytokine Modulation of TLR Expression and Activation in Mesenchymal Stromal Cells Leads to a Proinflammatory Phenotype J. Immunol., June 15, 2009; 182(12): 7963 - 7973. [Abstract] [Full Text] [PDF] M. Rafei, P. M. Campeau, A. Aguilar-Mahecha, M. Buchanan, P. Williams, E. Birman, S. Yuan, Y. K. Young, M.-N. Boivin, K. Forner, et al. Mesenchymal Stromal Cells Ameliorate Experimental Autoimmune Encephalomyelitis by Inhibiting CD4 Th17 T Cells in a CC Chemokine Ligand 2-Dependent Manner J. Immunol., May 15, 2009; 182(10): 5994 - 6002. [Abstract] [Full Text] [PDF] D. C. Vela, G. V. Silva, J. A.R. Assad, A. L.S. Sousa, S. Coulter, M. R. Fernandes, E. C. Perin, J. T. Willerson, and L. M. Buja Histopathological Study of Healing After Allogenic Mesenchymal Stem Cell Delivery in Myocardial Infarction in Dogs J. Histochem. Cytochem., February 1, 2009; 57(2): 167 - 176. [Abstract] [Full Text] [PDF] P. A. Walker, S. K. Shah, M. T. Harting, and C. S. Cox Jr Progenitor cell therapies for traumatic brain injury: barriers and opportunities in translation Dis. Model. Mech., January 1, 2009; 2(1-2): 23 - 38. [Abstract] [Full Text] [PDF] M. Rafei, J. Hsieh, S. Fortier, M. Li, S. Yuan, E. Birman, K. Forner, M.-N. Boivin, K. Doody, M. Tremblay, et al. Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction Blood, December 15, 2008; 112(13): 4991 - 4998. [Abstract] [Full Text] [PDF] R. Atoui, D. Shum-Tim, and R. C.J. Chiu Myocardial Regenerative Therapy: Immunologic Basis for the Potential "Universal Donor Cells" Ann. Thorac. Surg., July 1, 2008; 86(1): 327 - 334. [Abstract] [Full Text] [PDF] D. L. Coutu, J. H. Wu, A. Monette, G.-E. Rivard, M. D. Blostein, and J. Galipeau Periostin, a Member of a Novel Family of Vitamin K-dependent Proteins, Is Expressed by Mesenchymal Stromal Cells J. Biol. Chem., June 27, 2008; 283(26): 17991 - 18001. [Abstract] [Full Text] [PDF] N. Eliopoulos, M. Francois, M.-N. Boivin, D. Martineau, and J. Galipeau Neo-Organoid of Marrow Mesenchymal Stromal Cells Secreting Interleukin-12 for Breast Cancer Therapy Cancer Res., June 15, 2008; 68(12): 4810 - 4818. [Abstract] [Full Text] [PDF] H. A. Sadek and D. J. Garry Letter by Sadek and Garry Regarding Article, "Iron-Oxide Labeling and Outcome of Transplanted Mesenchymal Stem Cells in the Infarcted Myocardium" Circulation, April 8, 2008; 117(14): e306 - e306. [Full Text] [PDF] A. J. Nauta and W. E. Fibbe Immunomodulatory properties of mesenchymal stromal cells Blood, November 15, 2007; 110(10): 3499 - 3506. [Abstract] [Full Text] [PDF] I. Rasmusson, M. Uhlin, K. Le Blanc, and V. Levitsky Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes J. Leukoc. Biol., October 1, 2007; 82(4): 887 - 893. [Abstract] [Full Text] [PDF] F. Gieseke, B. Schutt, S. Viebahn, E. Koscielniak, W. Friedrich, R. Handgretinger, and I. Muller Human multipotent mesenchymal stromal cells inhibit proliferation of PBMCs independently of IFN{gamma}R1 signaling and IDO expression Blood, September 15, 2007; 110(6): 2197 - 2200. [Abstract] [Full Text] [PDF] M. Sundin, O. Ringden, B. Sundberg, S. Nava, C. Gotherstrom, and K. Le Blanc No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients Haematologica, September 1, 2007; 92(9): 1208 - 1215. [Abstract] [Full Text] [PDF] P. Batten, N. A Rosenthal, and M. H Yacoub Immune response to stem cells and strategies to induce tolerance Phil Trans R Soc B, August 29, 2007; 362(1484): 1343 - 1356. [Abstract] [Full Text] [PDF] R. A. Cahill, D. Wenkert, S. A. Perlman, A. Steele, S. P. Coburn, W. H. McAlister, S. Mumm, and M. P. Whyte Infantile Hypophosphatasia: Transplantation Therapy Trial Using Bone Fragments and Cultured Osteoblasts J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 2923 - 2930. [Abstract] [Full Text] [PDF] R. Romieu-Mourez, M. Francois, M.-N. Boivin, J. Stagg, and J. Galipeau Regulation of MHC Class II Expression and Antigen Processing in Murine and Human Mesenchymal Stromal Cells by IFN-{gamma}, TGF-beta, and Cell Density J. Immunol., August 1, 2007; 179(3): 1549 - 1558. [Abstract] [Full Text] [PDF] F. Locatelli, R. Maccario, and F. Frassoni Mesenchymal stromal cells, from indifferent spectators to principal actors. Are we going to witness a revolution in the scenario of allograft and immune-mediated disorders? Haematologica, July 1, 2007; 92(7): 872 - 877. [Full Text] [PDF] R. A. Campbell, T. H. Fischer, and A. S. Wolberg A Novel Use of Rehydrated, Lyophilized Platelets Increases Recombinant FVIIa Procoagulant Activity in a Model of Hemophilia. Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 1754 - 1754. [Abstract] [PDF] A. J. Nauta, G. Westerhuis, A. B. Kruisselbrink, E. G. A. Lurvink, R. Willemze, and W. E. Fibbe Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting Blood, September 15, 2006; 108(6): 2114 - 2120. [Abstract] [Full Text] [PDF] M. Sudres, F. Norol, A. Trenado, S. Gregoire, F. Charlotte, B. Levacher, J.-J. Lataillade, P. Bourin, X. Holy, J.-P. Vernant, et al. Bone Marrow Mesenchymal Stem Cells Suppress Lymphocyte Proliferation In Vitro but Fail to Prevent Graft-versus-Host Disease in Mice. J. Immunol., June 15, 2006; 176(12): 7761 - 7767. [Abstract] [Full Text] [PDF] J. L. Chan, K. C. Tang, A. P. Patel, L. M. Bonilla, N. Pierobon, N. M. Ponzio, and P. Rameshwar Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-{gamma} Blood, June 15, 2006; 107(12): 4817 - 4824. [Abstract] [Full Text] [PDF] N. Eliopoulos, R. F. Gagnon, M. Francois, and J. Galipeau Erythropoietin Delivery by Genetically Engineered Bone Marrow Stromal Cells for Correction of Anemia in Mice with Chronic Renal Failure J. Am. Soc. Nephrol., June 1, 2006; 17(6): 1576 - 1584. [Abstract] [Full Text] [PDF] B. Gangadharan, E. T. Parker, L. M. Ide, H. T. Spencer, and C. B. Doering High-level expression of porcine factor VIII from genetically modified bone marrow-derived stem cells Blood, May 15, 2006; 107(10): 3859 - 3864. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020